![Hussein Sweiti](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermogen: - $ op 31-08-2026
Hussein Sweiti formerly worked at enGene Therapeutics, Inc., as Chief Medical Officer from 2025 to 2026.
Dr. Sweiti received his doctorate degree from Ruprecht-Karls-Universität Heidelberg and graduate degree from Heinrich-Heine-Universität Düsseldorf.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-09-2025 | 0 ( -.--% ) | - $ | 31-08-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
| ENGENE THERAPEUTICS INC. | Hoofd Techniek/Wetenschap/O&O | 14-06-2026 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
| Bedrijven in privébezit | 4 |
|---|---|
Johnson & Johnson
 Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
Ruprecht-Karls-Universität Heidelberg
 Ruprecht-Karls-Universität Heidelberg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Heinrich-Heine-Universität Düsseldorf
 Heinrich-Heine-Universität Düsseldorf Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
enGene Holdings, Inc.
 enGene Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company that develops, manufactures and sells non-viral genetic medicines | Commercial Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau
